Illumina, General Atlantic and Viking Global Investors supplied $70m for Ginkgo Bioworks, a cell programming technology provider that has now raised more than $789m altogether.

Existing backer Ligand took part in a series C round that will fund late-stage clinical trials for Palvella Therapeutics' rare genetic disease drug candidates.

Q32 Bio has launched with $46m from investors including Sanofi Ventures and Children’s Hospital Colorado to target autoimmune and inflammatory diseases.

Atom Bioscience will use the capital from the series B round, which was co-led by Livzon Pharmaceutical, to advance its gout treatment into phase 2 trials.

Fuyo General Lease and Itochu Technology Ventures both invested as the cell-sorting technology developer completed a $15.3m round.

Gene sequencing corporate spinoff MGI Tech closed a $1bn series B round backed by IDG Capital and CPE Capital. The company offers an array of products, some of which have been used for Covid-19 detection and forms part of the promising space of genetics tech.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Blue Venture Fund and McKesson Ventures returned to reinvest in the cancer care analysis platform through a round that almost doubled its overall funding.

The diabetes treatment developer, which counts WL Gore and Johnson & Johnson as investors, has raised a further $27m for its latest round.

Philips Health Technology Ventures and UnityPoint Health Ventures have taken part in a $16.7m round for the telehealth technology provider.